Cargando…
Eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report
INTRODUCTION: Malignant ascites is often a sign of a terminal stage in several malignant diseases. To control ascites, drainage and intra-abdominal chemotherapy are often used in those patients but eradication of ascites is difficult and prognosis is poor. CASE PRESENTATION: A 55-year-old woman was...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613411/ https://www.ncbi.nlm.nih.gov/pubmed/19055844 http://dx.doi.org/10.1186/1752-1947-2-372 |
_version_ | 1782163179098341376 |
---|---|
author | Kimura, Hideki Iizasa, Toshihiko Ishikawa, Aki Yoshino, Mitsuru Shingyouji, Masato Kimura, Masaki Hirata, Tetushi Odaka, Akiko Matsubayasi, Keiko |
author_facet | Kimura, Hideki Iizasa, Toshihiko Ishikawa, Aki Yoshino, Mitsuru Shingyouji, Masato Kimura, Masaki Hirata, Tetushi Odaka, Akiko Matsubayasi, Keiko |
author_sort | Kimura, Hideki |
collection | PubMed |
description | INTRODUCTION: Malignant ascites is often a sign of a terminal stage in several malignant diseases. To control ascites, drainage and intra-abdominal chemotherapy are often used in those patients but eradication of ascites is difficult and prognosis is poor. CASE PRESENTATION: A 55-year-old woman was admitted to our hospital on 26 January 2007 with dyspnea, abdominal distention and oliguria. Abdominocentesis revealed peritoneal carcinomatosis resulting from abdominal recurrence from lung cancer. To alleviate the dyspnea and abdominal distention, we drained the ascites aseptically and infused them intravenously back into the patient after removal of tumor cells by centrifugation, and then concentration by apheresis. After the drainage of ascites, we intraperitoneally infused activated killer cells and dendritic cells from the patient's tumor-draining lymph nodes, together with 4.5 × 10(5)U interleukin-2 in 50 ml saline by 2.1 ml/hour infuser balloon. Drastic decreases in the tumor cell count and in ascite retention were observed after several courses of ascites drainage, intravenous infusion and intraperitoneal immunotherapy. The plasma protein level was maintained during the treatment notwithstanding the repeated drainage of ascites. Cell surface marker analysis, cytotoxic activities against autologous tumor cells and interferon-gamma examination of ascites suggested the possibility that these effects were mediated by immunological responses of activated killer cells and dendritic cells infused intraperitoneally. CONCLUSION: Combination of local administration of immune cells and infusion of concentrated cell free ascites may be applicable for patients afflicted with refractory ascites. |
format | Text |
id | pubmed-2613411 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-26134112009-01-03 Eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report Kimura, Hideki Iizasa, Toshihiko Ishikawa, Aki Yoshino, Mitsuru Shingyouji, Masato Kimura, Masaki Hirata, Tetushi Odaka, Akiko Matsubayasi, Keiko J Med Case Reports Case Report INTRODUCTION: Malignant ascites is often a sign of a terminal stage in several malignant diseases. To control ascites, drainage and intra-abdominal chemotherapy are often used in those patients but eradication of ascites is difficult and prognosis is poor. CASE PRESENTATION: A 55-year-old woman was admitted to our hospital on 26 January 2007 with dyspnea, abdominal distention and oliguria. Abdominocentesis revealed peritoneal carcinomatosis resulting from abdominal recurrence from lung cancer. To alleviate the dyspnea and abdominal distention, we drained the ascites aseptically and infused them intravenously back into the patient after removal of tumor cells by centrifugation, and then concentration by apheresis. After the drainage of ascites, we intraperitoneally infused activated killer cells and dendritic cells from the patient's tumor-draining lymph nodes, together with 4.5 × 10(5)U interleukin-2 in 50 ml saline by 2.1 ml/hour infuser balloon. Drastic decreases in the tumor cell count and in ascite retention were observed after several courses of ascites drainage, intravenous infusion and intraperitoneal immunotherapy. The plasma protein level was maintained during the treatment notwithstanding the repeated drainage of ascites. Cell surface marker analysis, cytotoxic activities against autologous tumor cells and interferon-gamma examination of ascites suggested the possibility that these effects were mediated by immunological responses of activated killer cells and dendritic cells infused intraperitoneally. CONCLUSION: Combination of local administration of immune cells and infusion of concentrated cell free ascites may be applicable for patients afflicted with refractory ascites. BioMed Central 2008-12-04 /pmc/articles/PMC2613411/ /pubmed/19055844 http://dx.doi.org/10.1186/1752-1947-2-372 Text en Copyright © 2008 Kimura et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Kimura, Hideki Iizasa, Toshihiko Ishikawa, Aki Yoshino, Mitsuru Shingyouji, Masato Kimura, Masaki Hirata, Tetushi Odaka, Akiko Matsubayasi, Keiko Eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report |
title | Eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report |
title_full | Eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report |
title_fullStr | Eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report |
title_full_unstemmed | Eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report |
title_short | Eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report |
title_sort | eradication of intractable malignant ascites by abdominocentesis, reinfusion of concentrated ascites, and adoptive immunotherapy with dendritic cells and activated killer cells in a patient with recurrent lung cancer: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613411/ https://www.ncbi.nlm.nih.gov/pubmed/19055844 http://dx.doi.org/10.1186/1752-1947-2-372 |
work_keys_str_mv | AT kimurahideki eradicationofintractablemalignantascitesbyabdominocentesisreinfusionofconcentratedascitesandadoptiveimmunotherapywithdendriticcellsandactivatedkillercellsinapatientwithrecurrentlungcanceracasereport AT iizasatoshihiko eradicationofintractablemalignantascitesbyabdominocentesisreinfusionofconcentratedascitesandadoptiveimmunotherapywithdendriticcellsandactivatedkillercellsinapatientwithrecurrentlungcanceracasereport AT ishikawaaki eradicationofintractablemalignantascitesbyabdominocentesisreinfusionofconcentratedascitesandadoptiveimmunotherapywithdendriticcellsandactivatedkillercellsinapatientwithrecurrentlungcanceracasereport AT yoshinomitsuru eradicationofintractablemalignantascitesbyabdominocentesisreinfusionofconcentratedascitesandadoptiveimmunotherapywithdendriticcellsandactivatedkillercellsinapatientwithrecurrentlungcanceracasereport AT shingyoujimasato eradicationofintractablemalignantascitesbyabdominocentesisreinfusionofconcentratedascitesandadoptiveimmunotherapywithdendriticcellsandactivatedkillercellsinapatientwithrecurrentlungcanceracasereport AT kimuramasaki eradicationofintractablemalignantascitesbyabdominocentesisreinfusionofconcentratedascitesandadoptiveimmunotherapywithdendriticcellsandactivatedkillercellsinapatientwithrecurrentlungcanceracasereport AT hiratatetushi eradicationofintractablemalignantascitesbyabdominocentesisreinfusionofconcentratedascitesandadoptiveimmunotherapywithdendriticcellsandactivatedkillercellsinapatientwithrecurrentlungcanceracasereport AT odakaakiko eradicationofintractablemalignantascitesbyabdominocentesisreinfusionofconcentratedascitesandadoptiveimmunotherapywithdendriticcellsandactivatedkillercellsinapatientwithrecurrentlungcanceracasereport AT matsubayasikeiko eradicationofintractablemalignantascitesbyabdominocentesisreinfusionofconcentratedascitesandadoptiveimmunotherapywithdendriticcellsandactivatedkillercellsinapatientwithrecurrentlungcanceracasereport |